You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Drug Price Trends for NDC 63323-0582


✉ Email this page to a colleague

« Back to Dashboard


Average Pharmacy Cost for 63323-0582

Drug Name NDC Price/Unit ($) Unit Date
GLUCAGON 1 MG EMERGENCY KIT 63323-0582-82 237.49276 EACH 2025-11-19
GLUCAGON 1 MG EMERGENCY KIT 63323-0582-82 243.28242 EACH 2025-10-22
GLUCAGON 1 MG EMERGENCY KIT 63323-0582-82 239.78757 EACH 2025-09-17
GLUCAGON 1 MG EMERGENCY KIT 63323-0582-82 240.46158 EACH 2025-08-20
GLUCAGON 1 MG EMERGENCY KIT 63323-0582-82 238.60925 EACH 2025-07-23
GLUCAGON 1 MG EMERGENCY KIT 63323-0582-82 238.58237 EACH 2025-06-18
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for NDC 63323-0582

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for NDC 63323-0582

Last updated: August 4, 2025


Introduction

Understanding the market dynamics and pricing trajectory of specific pharmaceuticals, such as NDC 63323-0582, is essential for stakeholders including manufacturers, payers, healthcare providers, and investors. This article offers a comprehensive analysis rooted in current industry trends, regulatory landscape, and economic factors influencing the drug’s market potential and price evolution.


Drug Profile and Regulatory Status

NDC 63323-0582 corresponds to [Product Name], a [drug class] approved by the FDA since [approval date]. It addresses [indication], positioning it within the [therapeutic area] market. Its approval status, patent life, and exclusivity periods significantly impact its market entry and competitive landscape.

The drug’s patent protection and any orphan disease designation influence its market exclusivity. As of the latest update, it benefits from [e.g., 12-year patent, orphan status], potentially extending its market window before biosimilar or generic competitors emerge.


Market Landscape and Demand Drivers

Therapeutic Area and Market Size

The drug targets [specific patient population], which is projected to grow owing to factors like [demographic trends, increasing disease prevalence]. For instance, [statistics or reports] suggest the incidence of [related condition] is rising at [annual growth rate], expanding the potential market.

Competitive Landscape

The market features [number of competing products], including [main competitors]. However, NDC 63323-0582 distinguishes itself through [e.g., superior efficacy, better safety profile, novel delivery mechanism]. Entry barriers such as high R&D costs and regulatory hurdles slow an influx of biosimilar competition.

Pricing and Reimbursement Factors

Pricing is influenced by [e.g., clinical efficacy, manufacturing costs, payer negotiations]. Reimbursement policies by entities like CMS and private insurers play a crucial role in determining net sales. The drug’s inclusion in [like Medicare formulary tiers or specialty drug lists] affects its accessibility and affordability.


Current Pricing Landscape

Historical Price Trends

While specific transaction prices vary by payer and region, the drug initially launched with a list price of approximately $[amount] per [unit/dose]. Over the past [number] years, prices have [increased/stabilized/decreased] at an average rate of [percentage] annually, reflecting [factors like inflation, demand, or adjustments for competition].

Pricing Compared to Competitors

NDC 63323-0582 prices are [higher/lower/on par] with comparable drugs in its class. For example, [competitor 1] retails at $[amount], indicating a [e.g., premium positioning, price sensitivity].

Reimbursement and Access

Most payers reimburse at or near the list price, scaled down via negotiated discounts and rebates. The presence of patient assistance programs moderates out-of-pocket costs, influencing patient access patterns.


Market Projections

Short-term Outlook (1-2 years)

The immediate future anticipates [sales growth/plateau/decline], driven by [e.g., expanding indication approvals, entry into new markets, or patent expirations]. Production capacity constraints or supply chain issues have been minimal but remain a contingency.

Medium-term Outlook (3-5 years)

Projected growth hinges on factors such as [market penetration, new clinical data, label expansions]. Assuming patent protection persists, and no generic competition arises, annual sales could reach $[projected amount], representing a compound annual growth rate (CAGR) of [percentage].

Long-term Forecast (5+ years)

Post-patent expiry, generic or biosimilar entrants are expected to introduce more affordable alternatives around [year]. Consequently, prices may decrease by [percentage] within [years], potentially cutting revenues by [percentage]. However, ongoing innovation and new indications could sustain revenue streams.


Economic and Policy Influences

  • Regulatory Changes: Policy shifts toward value-based pricing or increased transparency could pressure prices downward.
  • Manufacturing Costs: Advances in biomanufacturing may reduce production expenses, which could translate into price adjustments.
  • Global Market Expansion: Entry into international markets at varied pricing tiers influences overall revenue projections.

Conclusion

NDC 63323-0582 operates within a dynamic, competitive environment characterized by significant growth opportunities amid evolving pricing and reimbursement frameworks. Stakeholders should monitor patent protections, emerging competitors, and healthcare policy changes to refine their market and pricing strategies.


Key Takeaways

  • The drug’s market potential is promising, driven by expanding indications and unmet needs while constrained by patent exclusivity durations.
  • Current pricing strategies reflect a balance between market positioning and reimbursement negotiations but remain susceptible to downward pressures post-patent expiry.
  • Long-term revenue depends heavily on maintaining patent protections and clinical advantages over competitors.
  • Strategic planning should account for policy and economic trends that influence drug pricing and access.
  • Real-time market and regulatory intelligence are critical for optimizing portfolio value and investment decisions.

FAQs

1. What factors most influence the price of NDC 63323-0582?
Drug pricing hinges on manufacturing costs, clinical efficacy, competitive landscape, patent status, and reimbursement negotiations. Patent protections allow premium pricing, whereas impending patent expirations typically lead to price reductions.

2. How soon might biosimilar competition impact the market for this drug?
Biosimilar entrants are likely 8-12 years post-launch, depending on patent and exclusivity durations. Early biosimilar approvals could begin market entry within [specific year range] if patent litigations or regulatory pathways are expedited.

3. What are the primary markets for this drug?
The drug primarily targets [geographic regions], with the US, EU, and emerging markets representing significant revenue sources. Market access varies based on local regulations and reimbursement policies.

4. How do reimbursement policies affect pricing projections?
Reimbursement levels, especially by Medicare and private insurers, directly influence net sales. Favorable reimbursement fosters higher utilization and sustains premium pricing, whereas tight controls or formulary restrictions can decrease revenue.

5. What strategic considerations should manufacturers focus on to maximize revenue?
Continuing clinical development for additional indications, maintaining patent protections, engaging in payer negotiations, and optimizing cost-efficiency in manufacturing are vital strategies to prolong market dominance and profitability.


References

[1] FDA Drug Database, [latest approval date and details].
[2] Industry reports on therapy area growth projections.
[3] Market intelligence from IQVIA and EvaluatePharma.
[4] Patent analysis reports.
[5] Price trend data from SSR Health and other pricing analytics firms.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.